1 Min Read
June 9 (Reuters) - Medivir AB
* Enrollment completed in the MIV-711 osteoarthritis extension study and data monitoring committee recommendation to “go ahead” Source text for Eikon: Further company coverage: (Stockholm Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.